Its hard not to see the potential of such a business. The growth in age-related visual problems and elective refractory surgery are enormous. Does this company have the potential to pull it off, to deliver on promises. It's a credibility issue. They have had two ordinary results now. If they can turn things around this thing will move, but in the mean-time, I agree, there may be more pain. The graph looks particularly unpleasant. I personally, will wait for more positive signals as we move closer to the next result.
VGH Price at posting:
0.0¢ Sentiment: Sell Disclosure: Not Held